Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years
1. BDX lowered fiscal year 2025 guidance, estimating lower growth. 2. Reported Q1 2025 earnings beat but missed sales consensus. 3. Analysts downgraded BDX, citing declining organic growth expectations. 4. Goldman Sachs cut price target from $256 to $192. 5. William Blair downgrades BDX to Market Perform after poor updates.